ClinicalTrials.gg
RecruitingNCT06599619Updated Jan 26, 2026

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

An observational study in Melanoma, sponsored by John Kirkwood. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-26.

Primary conditionDysplastic Nevus SyndromeRegistry: MelanomaReclassifiedWhy we changed it
Registry
Melanoma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Dysplastic Nevus Syndrome
Why
  1. The study's title name Dysplastic Nevus Syndrome, a narrower term within Melanoma.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by John Kirkwood · Observational

How we know · 4 judgments

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Dysplastic Nevus Syndrome with a site in United States — 5 open to participants now, 6 under way, 1 of them phase 3. Dysplastic Nevus Syndrome · United States.

Planned enrollment
11th of 11
30 · median 265
Started
2025
the only one that year
Observational
11 of 17
3 open now
Registered
16th of 17
by date
Lead sponsor
2 of 17
John Kirkwood

Among the 17 studies in Dysplastic Nevus Syndrome with a site in United States, this one is the 11th largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2025, is one of 11 observational ones, and was the 16th registered.

Dysplastic Nevus Syndrome

24 studies on the registry are indexed under Dysplastic Nevus Syndrome; 7 are open to participants now.

Browse Dysplastic Nevus Syndrome studies →

Open to participants now

5 of the 17 studies in Dysplastic Nevus Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Dysplastic Nevus Syndrome studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Dysplastic Nevus Syndrome with a site in United States, or all of them as a file.
02

Study summary

This study will examine the impact of anti-programmed cell death 1 (PD1) therapy given in the approved adjuvant therapeutic regimens upon the morphologic, histopathologic, molecular and immunologic as well as genomic features of atypical/dysplastic nevi (A/DN) in patients with a prior documented melanoma of Stages IIB, IIC, IIIA, IIIB, or IIIC and concurrent presence of two or more atypical nevi.

Read the detailed description

Given the established efficacy of anti-PD1 therapy as an adjuvant treatment in both advanced nodal and earlier stage deep primary node negative melanoma, this study hypothesizes that anti-PD1 therapy may provide a basis for effective therapeutic prevention. To study if anti-PD1 therapy can help prevent the development of melanoma, this study will examine its effects upon atypical/dysplastic nevi, which are well established as non-obligate pre-cursor lesions that are markers of increased risk of melanoma. This single agent, adjuvant study will evaluate the impact of adjuvant anti-PD1 therapy on morphology, histopathology, immunologic/molecular features, and gene expression of atypical/dysplastic nevi present in patients with stage IIB-III melanoma. This study aims to determine if anti-PD1 therapy will increase CD8 T cell responses to melanoma antigens, resulting in immune surveillance and anti-tumor immune responses within A/DN. It postulates that in response to anti-PD1 therapy, the aggregate pigmentation of total nevi including atypical/dysplastic nevi and benign melanocytic nevi will decrease with a measurable morphologic response. This study also asserts that there will be histopathologic changes within A/DN including increased density of immune infiltrate and increased presence of regression features. Increased anti-tumor immune response measured by increased CD8, IFN-y, and PD-1 expression within nevi is anticipated, along with a decrease in genes involved in pathways of melanomagenesis, pigmentation, and inflammation.

03

Conditions studied

  • Melanoma

Browse trials for

Keywords

  • anti-PD1 therapy
  • immune checkpoint blockade
  • dysplastic nevi
  • BRAF and NRAS mutations
04

In context

Dysplastic Nevus Syndrome Reclassified

24 studies on the registry are indexed under Dysplastic Nevus Syndrome; 7 are open to participants now.

This study's planned enrollment of 30 is below the median of 283 across 16 observational studies indexed under Dysplastic Nevus Syndrome.

Browse Dysplastic Nevus Syndrome studies →

Lead sponsor

John Kirkwood is the lead sponsor of 8 studies on the registry; 3 are open to participants now.

Compared within Dysplastic Nevus Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Melanoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with a prior documented melanoma of Stages IIB, IIC, IIIA, IIIB, or IIIC and concurrent presence of two or more atypical nevi who have received anti-programmed cell death 1 (PD1) therapy given in the approved adjuvant therapeutic regimens.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must have at least two atypical nevi of ≥ 4 mm diameter.
  2. Subjects must have a current documented history of melanoma.
  3. Subject must be ≥ 18 years and if female of , must agree to practice effective per institutional SOC if sexually active.
  4. Subjects will have been deemed candidates for therapy with single agent anti-PD1 therapy.
  5. Subjects must give written to participate in this study with consent signed and dated prior to entry into trial.

Exclusion criteria

Exclusion Criteria:

  1. Patients with non-malignant diseases or indications that would preclude the administration of anti-PD1 therapy such as significant immune suppression or active disease requiring disease modifying, therapy, will be ineligible.
  2. Patients who have previously received anti-PD1 therapy
  3. Patients with history of other active, non-melanoma cancers
  4. Patients who are receiving other anti-neoplastic therapy.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients Treated with single agent, adjuvant anti-PD1 therapy

    Patients receiving single agent, adjuvant anti-PD1 therapy (given either as standard of care or as part of a separate investigational study)

    Drug: Single agent, adjuvant anti-PD1 therapy

Interventions

  • DrugNivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    One of the following Single-agent, adjuvant anti-PD1 therapies: Nivolumab is a type of targeted therapy drug called an immune checkpoint inhibitor (a type of immunotherapy). It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells. It works by keeping cancer cells from suppressing the immune system. Dose = 240 mg IV every 2 weeks/480 mg every 4 weeks or, Pembrolizumab is a monoclonal antibody and a type of immune checkpoint inhibitor that's used in cancer immunotherapy. It works by attaching to the PD-1 protein on the surface of T cells, which are immune cells. This prevents cancer cells from suppressing the immune system, allowing the immune system to attack and kill the cancer cells. Dose = 200 mg IV every 3 weeks/ 400 mg every 6 weeks

    Also known as: OPDIVO®, Keytruda, Pembrolizumab, Nivolumab

This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

07

What researchers measure

Primary outcomes

  1. Change in the aggregate pigmentation

    Percentage change in the total aggregate pigmentation including A/DN and benign melanocytic nevi. Percent change will be quantified from posterior trunk digital photographic images utilizing DermViz automated image comparison software.

    Time frame: Pre-treatment, up to 12 months

Secondary outcomes

  1. Change in predefined atypical nevi - size

    Change in size of predefined atypical nevi at the level of the individual nevus, as documented by dermoscopy. An expert clinician panel will evaluate pre- and post-treatment dermoscopic images in a blinded manner to score the visual features of nevus atypia.

    Time frame: Pre-treatment, up to 12 months

  2. Change in predefined atypical nevi - margin

    Change in margin of predefined atypical nevi at the level of the individual nevus, as documented by dermoscopy. An expert clinician panel will evaluate pre- and post-treatment dermoscopic images in a blinded manner to score the visual features of nevus atypia.

    Time frame: Pre-treatment, up to 12 months

  3. Change in predefined atypical nevi - pigmentation

    Change in pigmentation of predefined atypical nevi at the level of the individual nevus, as documented by dermoscopy. An expert clinician panel will evaluate pre- and post-treatment dermoscopic images in a blinded manner to score the visual features of nevus atypia.

    Time frame: Pre-treatment, up to 12 months

  4. Change in histopathologic features of A/DN - cellular infiltrate

    Histopathologic changes within atypical nevi that are biopsied will be assessed by an expert dermatopathologist for the dendritic cell and lymphocytic cell immune infiltrate.

    Time frame: Pre-treatment, up to 12 months

  5. Change in histopathologic features of A/DN - regression features

    Histopathologic changes within atypical nevi that are biopsied will be assessed by an expert dermatopathologist for regression features including fibrosis and vascularization.

    Time frame: Pre-treatment, up to 12 months

  6. Change in histopathologic features of A/DN - cytologic features

    Histopathologic changes within atypical nevi that are biopsied will be assessed by an expert dermatopathologist for cytologic features including nuclear size and atypia.

    Time frame: Pre-treatment, up to 12 months

  7. Change in histopathologic features of A/DN - dysplastic features

    Histopathologic changes within atypical nevi that are biopsied will be assessed by an expert dermatopathologist for dysplastic features of nevi including cell architecture.

    Time frame: Pre-treatment, up to 12 months

Other outcomes

  1. Change in Expression of SOX-10 and BRAF

    Quantify change in expression of key genes of melanomagenesis in A/DN in response to anti-PD1 therapy, measured via bulk RNA-sequencing performed on biopsied nevus specimens.

    Time frame: Pre-treatment, up to 12 months

  2. Change in CD-8 T lymphocytes

    Changes in the immune microenvironment of A/DN in response to anti-PD1 therapy. Changes in T cell subsets will be quantified and compared pre- and post-treatment via multiplex IHC and multiplex IF performed on biopsied specimens.

    Time frame: Pre-treatment, up to 12 months

  3. Change in T-regs

    Changes in the immune microenvironment of A/DN in response to anti-PD1 therapy. Changes in regulatory T cells will be quantified and compared pre- and post-treatment via multiplex IHC and multiplex IF performed on biopsied specimens.

    Time frame: Pre-treatment, up to 12 months

  4. Change in IFN-y immune transcriptional signature

    Changes in the immune microenvironment of A/DN in response to anti-PD1 therapy. Changes in IFN-y immune transcriptional signature will be quantified and compared pre- and post-treatment via multiplex IHC and multiplex IF performed on biopsied specimens.

    Time frame: Pre-treatment, up to 12 months

  5. Change in IL-6 immune transcriptional signature

    Changes in the immune microenvironment of A/DN in response to anti-PD1 therapy. Changes in Immune transcriptional signature will be quantified and compared pre- and post-treatment via multiplex IHC and multiplex IF performed on biopsied specimens.

    Time frame: Pre-treatment, up to 12 months

  6. Change in IL-10 immune transcriptional signature

    Changes in the immune microenvironment of A/DN in response to anti-PD1 therapy. IL-10 immune transcriptional signature will be quantified and compared pre- and post-treatment via multiplex IHC and multiplex IF performed on biopsied specimens.

    Time frame: Pre-treatment, up to 12 months

  7. Change in PD1 expression

    Changes in the immune microenvironment of A/DN in response to anti-PD1 therapy. Changes in PD1 expression will be quantified and compared pre- and post-treatment via multiplex IHC and multiplex IF performed on biopsied specimens.

    Time frame: Pre-treatment, up to 12 months

08

Study locations

1 of 1 sites recruiting
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
    Recruiting
    • Danielle L Bednarz, RN · Contactbednarzdl@upmc.edu · (412) 623-1191
    • Amy Rose, RN · Contactkennaj@upmc.edu · 4126478587
    • John M Kirkwood, MD · Principal investigator
    • Urvashi M Joshi, MD · Sub investigator
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for May 2029, 51 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2024
First posted
Sep 19, 2024
StartActual
Feb 20, 2025
Primary completionEst.
May 2029
CompletionEst.
May 2029
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06599619
Lead sponsor
John Kirkwood
Collaborators
Melanoma Research Foundation, VeyTel Inc.
Responsible party
John Kirkwood (Professor of Medicine, Immunology, and Dermatology, University of Pittsburgh) — Sponsor-investigator
First posted
Sep 19, 2024
Start date
Feb 20, 2025
Primary completion
May 2029 (estimated)
Completion
May 2029 (estimated)
Last update
Jan 26, 2026

Study contacts

Danielle L Bednarz, RN
Contact
bednarzdl@upmc.edu
(412) 623-1191
Amy Rose, RN
Contact
kennaj@upmc.edu
4126478587
John M Kirkwood, MD
principal investigator · UPMC Hillman Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion